CRESCENT BIOPHARMA, INC.
Crescent Biopharma is a clinical-stage biotechnology company developing cancer therapies for people with cancer. Its portfolio centers on two strategies: CR-001, a bispecific antibody designed to bind PD-1 and VEGF, and antibody drug conjugates (ADCs). CR-002 is a PD-L1-directed ADC with a topoisomerase payload, while CR-003 is an integrin beta-6-directed ADC licensed for development outside Greater China. Crescent is also developing CR-001 for use alone and in combinations with ADCs, and plans to expand its portfolio through internal development, its relationship with Paragon Therapeutics, and external sources. Crescent’s business is developing product candidates through clinical trials and seeking regulatory approvals for potential cancer treatments. It has an exclusive-rights partnership with Kelun covering CR-003 outside mainland China, Hong Kong, Macau, and Taiwan, and has granted Kelun exclusive rights to CR-001 in those territories. Crescent is headquartered in Waltham, Massachusetts.
No SEC Form 4 filings for $CBIO in the last 30 days.
See all $CBIO insider activity →Piper Sandler kept its Overweight rating on Crescent Biopharma but reduced its price target to $32 from $35, an 8.6% decrease. This implies a 122.7% upside from the Nov 12 close of $14.37.
HC Wainwright & Co. kept its Buy rating on Crescent Biopharma but raised its price target to $40 from $36, citing an 11.1% increase. This target suggests a 178.4% upside from the Nov 12 closing price of $14.37, according to the firm.
Crescent Biopharma (CBIO) reported a Q3 loss of $37.7 million, or 90 cents per share, missing analyst estimates of a 57-cent loss. Revenue was $3.1 million. The biotech company is based in Waltham, Massachusetts.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CBIO (CRESCENT BIOPHARMA, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 3 bearish.
Recent CBIO coverage spans financial news, earnings and corporate actions.
Piper Sandler kept its Overweight rating on Crescent Biopharma but reduced its price target to $32 from $35, an 8.6% decrease. This implies a 122.7% upside from the Nov 12 close of $14.37.
HC Wainwright & Co. kept its Buy rating on Crescent Biopharma but raised its price target to $40 from $36, citing an 11.1% increase. This target suggests a 178.4% upside from the Nov 12 closing price of $14.37, according to the firm.
Earnings miss likely drives the stock lower.
The new financial results and clinical milestones may increase short‑term volatility as investors price in upcoming data readouts.
Analyst upgrade with a high target may drive buying interest.
AlphAI scores every news story that mentions CBIO with an AI model for sentiment and relevance, and aggregates insider trades from CRESCENT BIOPHARMA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Piper Sandler kept its Overweight rating on Crescent Biopharma but reduced its price target to $32 from $35, an 8.6% decrease. This implies a 122.7% upside from the Nov 12 close of $14.37.
HC Wainwright & Co. kept its Buy rating on Crescent Biopharma but raised its price target to $40 from $36, citing an 11.1% increase. This target suggests a 178.4% upside from the Nov 12 closing price of $14.37, according to the firm.
Crescent Biopharma (CBIO) reported a Q3 loss of $37.7 million, or 90 cents per share, missing analyst estimates of a 57-cent loss. Revenue was $3.1 million. The biotech company is based in Waltham, Massachusetts.
CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy com
H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.
Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.
Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.
CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care
Stifel maintained a Buy rating and $28 target on Crescent Biopharma (NASDAQ:CBIO) after FDA clearance of its CR-002 drug. The stock trades at $13.94, down 28% in six months. Stifel expects trial data in 2027. Crescent raised $143.7M in a public offering. H.C. Wainwright upgraded CBIO to Buy with a $36 target.
H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.
